OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Gastrobase.it
Ematobase.it

Search results for "Urothelial cancer"

Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced urothelial cancer ( also known as bladder cancer ) presented at ESMO ( European Society f ...


A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial carcinoma ( UC ) who were treated with Gemcitabine and Carboplatin ...


Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...


Pembrolizumab ( Keytruda ), an anti–PD-1 antibody, demonstrated antitumor activity and acceptable safety in patients with recurrent or metastatic PD-L1–positive urothelial cancer enrolled in the phase ...


Immune checkpoint blockade may play a role in the treatment of metastatic urothelial cancer ( mUC ). However, the role of CTLA4 blockade, the impact of chemotherapy on immune cell populations, and the ...


The results for Nivolumab ( Opdivo ) in the cohort of patients with metastatic urothelial cancer ( n=78 ), the most common type of bladder cancer, after Platinum-based therapy from CheckMate -032, a p ...


Updated results from the phase 3 KEYNOTE-045 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial carcinoma with disease progre ...


Although some patients with Platinum-pretreated metastatic urothelial cancer ( mUC ) demonstrated good responses to Nivolumab monotherapy, the response rate and survival were higher with combined Nivo ...